GgoogleNL first seen 1 d ago, last 1 d ago, peak #6

Retatrutide draws attention as next obesity drug

Original: retatrutide

Interest is growing in retatrutide, Eli Lilly's experimental obesity and diabetes drug, which follows in the footsteps of tirzepatide and semaglutide. Discussion centres on its triple-hormone mechanism and trial results suggesting greater weight loss than existing GLP-1 medicines. Commentators frame it as the next step in the fast-expanding market for weight-loss injections, though it remains under development and not yet approved.

Why now: Ongoing excitement over the next generation of GLP-1 obesity drugs after tirzepatide's success.

Eli Lillyretatrutidetirzepatide

Open on google →

Evidence

• tirzepatide news · BusinessWorld Online

Elsewhere

• GgoogleIT #5 · 5 d ago
• GgoogleAU #10 · 6 d ago
• GgoogleGB #6 · 6 d ago
• GgoogleUS #4 · 7 d ago
• GgoogleBR #7 · 20 d ago

API: https://socialmediatrends-api.osmike.com/v1/trends/2823576